drugset / Trial / NCT06842823
A Study of Navenibart in Participants With Hereditary Angioedema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Timeline
- Start
- 2025-03-20
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navenibart | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Navenibart | Monoclonal antibody | 600 mg | Subcutaneous |